Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

564
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.8K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Oncology: Emerging Molecular Methods for Drug Target Discovery.

Current topics in medicinal chemistry·2026
Same author

PROTAC-Based Therapeutics: From Design to Clinical Potential in Neurodegenerative Disease.

Current neuropharmacology·2026
Same author

Recent Advances in Guillain-Barré Syndrome: Neurological Disorder, Pathophysiology, Diagnosis, Treatment, and Challenges.

Current neuropharmacology·2026
Same author

Next-Generation Antioxidants in Cardiovascular Disease: Mechanistic Insights and Emerging Therapeutic Strategies.

Antioxidants (Basel, Switzerland)·2026
Same author

Phytochemicals and REDOX Modulation: Molecular Mechanisms, Clinical Relevance, and Therapeutic Perspectives.

Antioxidants (Basel, Switzerland)·2026
Same author

Antioxidant Natural Compounds Integrated with Targeted Protein Degradation: A Multi-Modal Strategy for Alzheimer's Disease Therapy.

Antioxidants (Basel, Switzerland)·2025

Related Experiment Video

Updated: Mar 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Emerging Therapies in Hypercholesterolemia: Mechanistic Insight and Key Molecular Inhibitors.

Desh Deepak Singh1

  • 1Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, 303002, India.

Current Medicinal Chemistry
|March 15, 2026
PubMed
Summary

Hypercholesterolemia management is evolving beyond statins. Novel therapies target cholesterol synthesis and absorption, offering personalized cardiovascular risk reduction.

Keywords:
Hypercholesterolemiacardiovascular risk managementinhibitorslipid-lowering therapynovel drug targetstherapeutic innovation.

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • Hypercholesterolemia is a major cardiovascular disease risk factor.
  • Current lipid-lowering therapies have limitations like side effects and variable efficacy.
  • Advances in understanding lipid metabolism drive the development of new treatments.

Purpose of the Study:

  • To review cholesterol biosynthesis, hypercholesterolemia pathophysiology, and diagnosis.
  • To analyze current and emerging lipid-lowering strategies.
  • To inform future personalized and sustainable hypercholesterolemia treatments.

Main Methods:

  • Literature review of cholesterol metabolism and therapeutic targets.
  • Analysis of novel agents including PCSK9 inhibitors, ATP-Citrate lyase inhibitors, and siRNA.
  • Discussion of nutraceuticals and gene-editing strategies.

Main Results:

  • Emerging therapies simultaneously modulate LDL cholesterol absorption, transport, and synthesis.
  • Novel agents offer new mechanisms beyond traditional treatments.
  • Personalized approaches are key for effective cardiovascular risk management.

Conclusions:

  • Continued innovation in lipid-lowering is crucial for cardiovascular health.
  • Emerging therapies represent a significant advancement in managing hypercholesterolemia.
  • Future treatments will focus on precision and sustainability for tailored patient care.